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ABSTRACT
Background. We conducted a meta-analysis to deter-
mine the effects of supervised exercise training on peak
oxygen consumption (VO2peak) in adults with cancer.
Methods. A literature review using Ovid MEDLINE
(1950 –2010), the Cochrane Central Register of Con-
trolled Trials (1991–2010), AMED (1985–2010), Em-
base (1988 –2010), PubMed (1966 –2010), Scopus
(1950–2010), and Web of Science (1950–2010) was per-
formed to identify randomized controlled trials exam-
ining the effects of supervised exercise training on
measurement of VO2peak (via gas exchange analysis) in
adults with cancer. Studies were selected using prede-
termined criteria, and two independent reviewers ex-
tracted data. Weighted mean differences (WMDs) were
calculated using random effect models.
Results. Six studies evaluated VO2peak involving a to-
tal of 571 adult cancer patients (exercise, n  344; usual
care control, n  227). Pooled data indicated that exer-
cise training was associated with a statistically signifi-
cant increase in VO2peak (WMD, 2.90 mlkg
1min1;
95% confidence interval [CI], 1.16–4.64); however, sig-
nificant heterogeneity was evident in this estimate (I2,
87%). Usual care (control) was associated with a signif-
icant decline in VO2peak from baseline to postinterven-
tion (WMD, 1.02 mlkg1min1; 95% CI, 1.46 to
0.58; I2, 22%). Sensitivity analyses indicated superior
improvements in VO2peak for studies conducted for a
shorter duration (<4 months) and following the com-
pletion of adjuvant therapy (p-values < .001). Exercise
training was not associated with a higher incidence of
adverse events, although safety was not rigorously mon-
itored or reported.
Conclusions. Supervised exercise training is associ-
ated with significant improvements in VO2peak follow-
ing a diagnosis of early-stage cancer, with minimal
adverse events. The Oncologist 2011;16:112–120
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INTRODUCTION
It is well established that cardiorespiratory fitness as well as
change in cardiorespiratory fitness are powerful predictors
of mortality in healthy adults as well as those with cardio-
vascular disease (CVD), even after controlling for tradi-
tional CVD risk factors [1–5]. Maximal or peak oxygen
consumption (VO2peak) provides the gold standard mea-
surement of cardiorespiratory fitness and is used widely in
numerous clinical and research applications [6].
Emerging evidence indicates that VO2peak also may be a
parameter of central importance following a diagnosis of
cancer. Prior to surgical resection, VO2peak is a strong pre-
dictor of perioperative or postoperative complication risk in
patients with non-small cell lung cancer (NSCLC) [7–10].
VO2peak is also centrally implicated in the etiology of cer-
tain cancer therapy–induced late effects. Specifically,
VO2peak is a predictor of anthracycline and trastuzumab-
induced left ventricular dysfunction and CVD risk profile
(e.g., blood pressure, lipid profile, c-reactive protein) as
well as global quality of life (QOL) and fatigue in patients
with solid malignancies [11–13]. Finally, there is evidence
from one report that VO2peak is also a strong independent
predictor of survival in NSCLC patients even after control-
ling for traditional prognostic factors [14].
Unfortunately, cancer patients have marked reductions
in VO2peak. In a series of studies by our group spanning the
entire cancer survivorship continuum (i.e., diagnosis to pal-
liation), we observed that VO2peak is consistently 30% be-
low that of age- and sex-matched sedentary individuals
without a history of cancer [15, 16]. The precise causes of a
poor VO2peak remain to be elucidated but likely reflect nor-
mal age-related exercise limitation together with additional
direct (injury to the cardiovascular system) and indirect
(toxicities secondary to treatment) effects of cytotoxic ther-
apy that, in combination, adversely impact the organ com-
ponents that govern exercise tolerance [17].
Numerous studies report that structured exercise train-
ing is associated with significant improvements in mea-
sures of cardiorespiratory fitness and related outcomes
across a broad range of oncology settings [18–21]. How-
ever, the current evidence base is fraught with important
methodological limitations, including nonrandomized de-
signs, small sample sizes, different exercise training modes
(aerobic and/or resistance training), and determination of car-
diorespiratory fitness using non-VO2peak measures. To clarify
this issue, we employed the meta-analysis approach to deter-
mine the effect of exercise training on VO2peak in adult cancer
patients. A secondary aim was to examine whether the effects
of exercise on VO2peak differed as a function of exercise inter-
vention (e.g., type, intensity, duration) or clinical characteris-
tics (e.g., cancer type, treatment status).
METHODS
Search Strategy and Inclusion Criteria
A comprehensive literature review was conducted using
Ovid MEDLINE (1950–2010), the Cochrane Central Reg-
ister of Controlled Trials (1991–2010), AMED (1985–
2010), Embase (1988 –2010), PubMed (1966 –2010),
Scopus (1950 –2010), and Web of Science (1950 –2010)
with the following Medical Subject Heading terms and text
words: oncology, cancer, neoplasms, malignancies, exer-
cise, exercise therapy, and exercise training. Relevant ref-
erence lists were also manually searched.
Randomized controlled trials (RCTs) involving adult
patients with histologically confirmed cancer that allocated
subjects to a supervised exercise training or concurrent non-
exercise control group were deemed eligible. Supervised
exercise training was defined as interventions consisting of
aerobic, resistance, or the combination of aerobic and resis-
tance training as opposed to unsupervised or home-based in-
terventions. Additionally, all eligible studies were required to
report a measurement of cardiorespiratory fitness via a cardio-
pulmonary exercise test (CPET) with gas exchange analysis
(to permit assessment of VO2peak). Studies with a participant
mean age 18 years, that were not written in English, that
were a review article only, and that did not assess the indepen-
dent effects of exercise training were excluded.
Study Selection, Data Extraction, and Quality
Assessment
Two authors (C.L.B. and E.N.P.) independently evaluated
study eligibility by reviewing the titles and abstracts of all
potential citations according to the inclusion criteria. The
same authors independently performed data extraction us-
ing standardized data abstraction forms. Disagreements
were resolved by consensus in discussion with a third inde-
pendent author (M.H.). When required, the primary authors
were contacted to clarify ambiguous experimental procedures
and/or results or provide additional data not provided in the
published manuscript. Methodological quality of eligible stud-
ies was assessed using the Oxford quality scoring system and
Schulz approach to allocation concealment [22]. The risk for
bias was assessed with the Cochrane criteria [23].
Data Synthesis and Analysis
For each eligible study, the effect size of exercise train-
ing was calculated using the change in VO2peak
(mlkg1min1) from baseline to postintervention for the
exercise and nonexercise control groups. In circumstances
when the change from baseline data or corresponding stan-
dard deviations were not available, these values were cal-
culated using standard statistical methods assuming a
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correlation of 0.50 between the baseline and postinterven-
tion scores within each subject [24]. Data from all eligible
studies were combined as weighted mean differences
(WMDs) with 95% confidence intervals (CIs) using the
random effects model. Statistical analyses were conducted
using Review Manager Software (RevMan 5.0; The Co-
chrane Collaboration, Oxford, UK). The primary analysis
compared the effect of exercise training, regardless of ex-
ercise prescription characteristics, with that of the non-
exercise control on VO2peak. Sensitivity analyses were per-
formed to investigate whether the effects of exercise on
VO2peak differed as a function of exercise intervention or
clinical characteristics (e.g., cancer type, treatment status).
Heterogeneity was quantified using the I2 statistic. I2
evaluates the percentage of total variation across included
studies attributed to heterogeneity as opposed to chance. A
value 50% is considered substantial heterogeneity [25].
The Deeks’ 2 test was conducted to test for significant het-
erogeneity reduction in partitioned subgroups [26]. The fol-
lowing subgroup analyses were conducted to investigate
possible sources of heterogeneity: (a) intervention length
(4 months versus 4 months), (b) gender/primary cancer di-
agnosis (all females/breast cancer versus all males/prostate
cancer versus mixed), and (c) treatment status (postsurgery
and completion of adjuvant therapy versus postsurgery and
during adjuvant therapy versus mixed). Publication bias was
tested visually using a funnel plot [27] and quantitatively using
the Begg adjusted-rank correlation test [28] and Egger regres-
sion asymmetry test [29]. Tests were performed using Stata
11.0 (Stata Corporation, College Station, TX).
RESULTS
In total, 2,855 potential citations were identified; after ini-
tial review; 35 papers were deemed eligible and underwent
full review (Fig. 1). The major reasons for exclusion were:
(a) inclusion of participants without a histological diagnosis
of cancer, (b) absence of an exercise intervention, and (c)
review article. Upon further review, 29 papers were further
excluded; reasons for exclusion were: (a) studies did not
perform a supervised exercise intervention or did not con-
duct a direct measure of VO2peak, (b) insufficient data were
presented in the paper, (c) exercise training was combined
with a concurrent complementary intervention, and (d) no
“usual care” control group. Thus, six trials were deemed el-
igible [20, 21, 30–33] and included in the primary analysis.
Study Characteristics
Study characteristics are provided in Table 1. Three studies
performed a two-arm RCT (aerobic training versus control
[20, 31] or the combination of aerobic and resistance train-
ing versus control [33]) and three conducted a three-arm
RCT comparing either different types of exercise (aerobic
training versus resistance training) [21, 32] or intensities of
aerobic training (low intensity versus moderate intensity)
[30]. Three of the six studies were conducted in women
with early-stage breast cancer [31–33]; the other studies
were conducted among patients with prostate cancer
(n  1) [21], non-Hodgkin’s lymphoma (n  1) [20], and
a combination of colon or breast cancer (n  1) [30].
Three studies were conducted following the completion
of definitive adjuvant therapy (i.e., chemotherapy or ra-
diation) [30, 31, 33], two were conducted during defini-
Figure 1. Selection process of eligible studies.
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tive cytotoxic therapy [21, 32], and one included patients
both receiving and following the completion of therapy
[20]. No studies reported performing continuous electro-
cardiogram monitoring during CPET whereas two stud-
ies reported monitoring heart rate during exercise
training sessions [21, 30]. The methodological quality of
trials is presented in Table 2.
Exercise Intervention Characteristics
The exercise intervention characteristics of included stud-
ies are provided in Table 3. Intervention lengths were in the
range of 8–24 weeks. In all studies, exercise was prescribed
3 times per week, with session durations in the range, on
average, of 14–45 minutes. All studies reported prescribing
“moderate-to-high intensity” exercise, defined as 40%–
80% of peak heart rate, heart rate reserve, or VO2peak ob-
tained from the baseline cardiopulmonary exercise test,
whereas one prescribed “low-intensity” training (25%–
40% of baseline heart rate reserve). Aerobic training alone
was the form of exercise training in three studies [20, 31,
32], two compared aerobic training only with resistance
training only [21, 32], and one tested the combination of
aerobic and resistance training [33].
Effect of Exercise Training on VO2peak
Six studies examined the effect of exercise training on
VO2peak, with 344 participants in the exercise groups and
227 participants in the nonexercise groups. The baseline
mean VO2peak was not different between groups in any
study (p  .05). Pooled data indicated that exercise training
was associated with a statistically significant increase in
VO2peak (WMD, 2.90 mlkg
1min1; 95% CI, 1.16–4.64);
however, significant heterogeneity was evident in this esti-
mate (I2, 87%) (Fig. 2). Usual care (control) was associated
with a significant decline in VO2peak from baseline to
postintervention (WMD, 1.02 mlkg1min1; 95% CI,
1.46 to 0.58; I2, 22%) There was no evidence of publi-
cation bias (Begg adjusted-rank correlation test, p  .71;
Egger regression asymmetry test, p  .69).
Effect of Exercise Training on VO2peak by
Exercise Intervention or Clinical Characteristics
Sensitivity analyses were conducted to investigate whether
the effects of exercise on VO2peak differed as a function of
exercise intervention or clinical characteristics. However,
given the small number of eligible studies, it was only fea-
sible to conduct sensitivity analyses based on intervention
length (4 months versus 4 months), therapy status (dur-
ing versus following adjuvant therapy), and exercise mo-
dality (aerobic only versus resistance only). Concerning
intervention length, for studies conducted for 4 months,
the overall effect size was 1.21 mlkg1min1 (two studies,
363 patients; WMD, 1.21 mlkg1min1; 95% CI, 0.50–
1.92; I2, 0%) favoring exercise training. The corresponding
pooled effect size for studies 4 months was 4.26
mlkg1min1 (four studies, 208 patients; WMD, 4.26
mlkg1min1; 95% CI, 2.92–5.60) favoring exercise
training, although moderate heterogeneity was evident in
this estimate (I2, 43%). The difference between subgroups
was significant (2, 33.49; p  .001) favoring studies con-
ducted for 4 months. For therapy status, in studies con-
ducted during adjuvant therapy, the pooled effect size was
1.21 mlkg1min1 (two studies, 363 patients; WMD, 1.21
mlkg1min1; 95% CI, 0.50–1.92; I2, 0%) favoring exer-































On 121 80 41 66 0%  NR NR
Courneya et al.
(2007) [32]
Breast Early On 242 160 82 49 100%  Hypertension, 7% NR
Herrero et al.
(2006) [33]
Breast Early Off 16 8 8 50 100% Sx, 100%; CT, 100% NR NR
Courneya et al.
(2003) [31]
Breast Early Off (46%
on ET)








Early Off 18 12 6 54 83% Sx, 61%; RT, 63%;
CT, 88%
NR NR
aOn treatment defined as undergoing primary adjuvant therapy (i.e., radiotherapy, chemotherapy); off treatment defined as
completion of primary adjuvant therapy.
bOnly for studies conducted following the completion of primary adjuvant therapy.
Abbreviations: CT, chemotherapy; ET, endocrine therapy, NR, not reported; RT, radiation therapy; Sx, surgery.
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cise training. The corresponding pooled effect size for
studies conducted following the completion of therapy
was 3.36 mlkg1min1 (three studies, 86 patients;
WMD, 3.36 mlkg1min1; 95% CI, 2.20 – 4.53; I2, 0%)
favoring exercise training. The difference between sub-
groups was significant (2, 38.62; p  .001) favoring
studies conducted after therapy completion (Fig. 3).
Only two studies directly compared aerobic training with
resistance training, with contrasting results. Overall,
there was no significant difference in VO2peak as a func-





Burnham and Wilcox (2002) [30] Matched on VO2peak and randomly assigned to groups Yes
Courneya et al. (2003) [31] Stratified by adjuvant therapy and randomly assigned to groups Yes
Herrero et al. (2006) [33] Not reported UN
Courneya et al. (2007) [32] Stratified by center and chemotherapy and randomly assigned to groups Yes
Courneya et al. (2009) [20] Stratified by disease type and treatment and randomly assigned to groups Yes
Segal et al. (2009) [21] Stratified by duration of ADT and randomly assigned to groups Yes
Allocation concealment
Burnham and Wilcox (2002) [30] Not reported UN
Courneya et al. (2003) [31] Block permutation used to generate allocation sequence within strata Yes
Herrero et al. (2006) [33] Allocation concealment unclear UN
Courneya et al. (2007) [32] Allocation sequence generated at coordinating center and concealed from
project directors
Yes
Courneya et al. (2009) [20] Generated independently and concealed in opaque envelopes Yes




Burnham and Wilcox (2002) Not reported UN
Courneya et al. (2003) [31] Outcome assessors blinded to group assignment performed testing and
determined scores preintervention/postintervention
Yes
Herrero et al. (2006) [33] Outcome assessors blinded to group assignment measured outcome
variables
Yes
Courneya et al. (2007) [32] Not reported whether outcome assessors were blinded to group
assignment
UN
Courneya et al. (2009) [20] Outcome assessors not always blinded to group assignment No
Segal et al. (2009) [21] Not reported whether outcome assessors blinded to group assignment No
Incomplete (VO2peak) data
Burnham and Wilcox (2002) [30] One control subject performed exercise training but was excluded; to
maintain matched group status, two subjects matched with excluded
control removed from analysis
No
Courneya et al. (2003) [31] Attrition/reasons for loss to follow-up reported Yes
Herrero et al. (2006) [33] All subjects completed pre-exercise/postexercise tests Yes
Courneya et al. (2007) [32] Reasons for not completing postintervention assessments uncertain UN
Courneya et al. (2009) [20] Attrition/reasons for loss to follow-up reported Yes
Segal et al. (2009) [21] Reasons for not completing postintervention exercise test uncertain UN
Selective outcome reporting
All studies Study protocol available and prespecified outcomes reported Yes
Other sources of bias
All studies Appear to be free from other sources of bias Yes
Yes indicates a low risk for bias; No indicates a high risk for bias.
Abbreviations: ADT, androgen deprivation therapy; UN, unclear risk for bias.
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tion of exercise modality (WMD, 0.78 mlkg1min1;
95% CI, 2.45 to 0.88; I2, 75%).
Adherence, Loss to Follow-Up, and Adverse
Events
The mean lost-to-follow-up rate was 8.1%  7.2% (range,
0%20%); there was no evidence for different lost-to-
follow-up rates between the exercise and control groups.
The mean adherence rate was 88.7%  10.1% (range,
70.2%98.4%); five of six studies reported an adherence
rate 80% [20, 21, 30, 31, 33]. Finally, all studies reported
that adverse events (AEs) were monitored during study
conduct. Two AEs were reported during cardiopulmonary
exercise testing, nine were reported during exercise train-
ing, and two were reported in control participants; a total
patient AE rate of 13 per 571 adult patients (2.3%) was
found. The most serious AE was a myocardial infarction
during aerobic training [21].
DISCUSSION
The principal finding of this meta-analysis was that rela-
tively short-term, structured, moderate-intensity exercise
training is associated with significant improvements in the
VO2peak in select curative-intent cancer patients both during
and following adjuvant therapy. Specifically, the WMD in
VO2peak was 2.91 mlkg
1min1 from baseline to postint-
ervention, favoring exercise training. The magnitude of
change is similar to that reported in a prior meta-analysis
that included three studies (two were unpublished disserta-
tions) in women with early breast cancer; McNeely et al.
[34] found that VO2peak increased 3.39 mlkg
1min1 with
exercise training, involving 95 patients in total. The prog-
nostic relevance of this improvement in adult cancer pa-
tients is not yet known; however, Myers et al. [1] and Gulati
et al. [35] found that the Framingham Risk Scoreadjusted
mortality risk decreased by 12% and 17% for every 1-MET
(3.5 mlkg1min1) difference in aerobic capacity among
Table 3. Exercise intervention characteristics




range/session Intensity (range) Monitoring
Courneya et al.
(2009) [20]
Aerobic training CE 12 wks 3 15–45 minutes 60%75% VO2peak  x1 INT
session in last month at 100%
VO2peak
NR







sets  8 reps













sets  8 reps











1–3 sets  8–15 reps























Abbreviations: BP, blood pressure; CE, cycle ergometry; ET, elliptical trainer; HR, heart rate; HRmax, heart rate maximum;
HRR, heart rate reserve; INT, interval; LE, lower extremity; NR, not reported; RM, repetition maximum; SC, stair climber;
TM, treadmill; UE, upper extremity; x1, one time/wk of interval training.
Figure 2. Pooled effects of supervised exercise training, compared with usual care (control), on cardiorespiratory fitness (peak
oxygen consumption, VO2peak).
Abbreviations: CI, confidence interval; SD, standard deviation.
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asymptomatic men and women, respectively. It is notewor-
thy that the beneficial effects of exercise training were ob-
served with minimal AEs. In total, 13 AEs were reported
across six studies, for a total AE rate of 2.3%. However, the
performance (monitoring) of VO2peak assessment did not
comply with CPET recommendations for clinical popula-
tions [6] or cancer patients [36]. In addition, no study
adopted a standardized method for monitoring or reporting
nonexercise-related AEs. As such, it is not clear whether the
low incidence of AEs reflects the true safety of CPET/
exercise training in cancer patients or less than optimal
monitoring/reporting of AEs. Cancer is a heterogeneous
disease varying considerably in location, pathogenesis, and
therapeutic management; thus, the risk for an exercise-
related AE is likely highly dependent on these factors. Un-
fortunately, given the low incidence of AEs, it was not
possible to investigate this question. We stress that future
studies should strive to comprehensively monitor and re-
port AEs when conducting exercise intervention studies in
the oncology setting [36].
A finding of major importance is the significant decline
in VO2peak among patients assigned to the usual care control
groups. In cross-sectional studies, we found that the
VO2peak of cancer patients was consistently 30% below
that of age- and sex-matched sedentary but otherwise
healthy individuals [13, 15, 16, 37]. The present finding
suggests that, without exercise training, VO2peak will re-
main low or become even further impaired, particularly
during adjuvant therapy. The clinical importance of this
finding cannot be overstated. First, VO2peak is a strong, in-
dependent predictor of mortality in humans with and with-
out CVD [1–5]. Recent work by our group found that,
relative to patients with a low VO2peak (13
mlkg1min1), moderate (13.9–16.9 mlkg1min1) and
high (17 mlkg1min1) VO2peak levels were associated
with a 21%24% lower all-cause mortality rate in presur-
gical NSCLC patients. A 1.0 mlkg1min1 decrease in
VO2peak, a reduction similar to that observed in patients ran-
domized to the nonexercise control groups, was associated
with a 4% greater mortality rate [14]. Second, Paterson et
al. [38] demonstrated that a minimum VO2peak of 15
mlkg1min1 in women and 18 mlkg1min1 in men
aged 85 years was necessary for full and independent living
(e.g., garden activities, walking up stairs). Alarmingly, a
large proportion of adult cancer patients do not meet this
minimum threshold, further highlighting the critical impor-
tance of exercise-based rehabilitation following diagnosis.
Finally, VO2peak is associated with a broad range of relevant
outcomes in cancer patients, including surgical complica-
tion risk, certain therapy late effects, global QOL, and fa-
tigue [9, 11–13, 15, 16, 39].
With only six eligible trials, sensitivity analyses were
difficult, although significant differences were indicated
for two parameters: exercise length and therapy status. Sur-
prisingly, shorter duration exercise interventions (4
months) were associated with superior VO2peak improve-
ments than in those of longer duration (4 months). This
finding may be an artifact of when the longer duration stud-
ies were conducted as opposed to real differences in inter-
vention length per se. Longer duration studies were, for the
most part, conducted during cytotoxic therapy, when
smaller improvements in VO2peak are expected. The sensi-
Figure 3. Pooled effects of supervised exercise training, compared with usual care (control), on cardiorespiratory fitness (peak
oxygen consumption, VO2peak) by treatment status.
Abbreviations: CI, confidence interval; SD, standard deviation.
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tivity analysis indicating superior VO2peak improvements
following rather than during adjuvant therapy supports this
notion. Structured exercise interventions in healthy (non-
diseased) adult populations typically report an 15% in-
crease in VO2peak with aerobic-based training following
traditional prescription guidelines (3–5 days per week at
50%75% of baseline VO2peak for 12–15 weeks) [40, 41].
Despite exercise studies in cancer patients employing sim-
ilar exercise prescriptions, the magnitude of the VO2peak
improvement appears lower, suggesting that the use of cy-
totoxic therapy may attenuate normal cardiovascular and/or
skeletal muscle adaptations to exercise training [32, 37].
The reasons for these divergent findings are not known but
likely relate to differences in the extent and causes of exer-
cise limitation between healthy adults and those with can-
cer. In addition to the normal effects of aging, cancer
patients are also subject to cytotoxic therapyinduced
injury together with profound deconditioning that dra-
matically depletes the compensatory abilities of the car-
diovascular reserve [17]. In addition, these effects are
further compounded by treatment-associated weight gain,
which also impacts VO2peak [42]. Studies investigating the
limitations to exercise, and underlying molecular mecha-
nisms, in cancer patients both during and following therapy
are warranted to ensure the optimal efficacy of exercise in
the oncology setting.
Caution is warranted when interpreting the present re-
sults given the significant heterogeneity evident in the pri-
mary and sensitivity analyses. In an effort to minimize
heterogeneity, we only selected RCTs that included a mea-
surement of VO2peak via expired gas exchange analysis.
Upon closer inspection, the significant heterogeneity is not
surprising given the stark between-study differences in can-
cer diagnosis, cytotoxic therapy, disease stage, and exercise
prescription characteristics. There is little doubt that the
field of exercise oncology has made significant progress
over the past decade; however, findings of our meta-analy-
sis, and prior reviews [34, 43], clearly demonstrate that the
current evidence base is emergent, with many fundamental
questions (e.g., optimal prescription, timing, and setting of
exercise, effects of exercise on tumor biology, and thera-
peutic efficacy) remaining to be addressed. A major goal of
exercise oncology research is to establish evidence-based
exercise rehabilitation/physical activity guidelines to max-
imize the health and longevity of persons following a can-
cer diagnosis. Clearly, more studies are required to inform
such guidelines, but simply increasing the absolute number
will not address the current limitations. Instead, in order to
advance the field, it is critical that the next generation of
studies logically build on and extend current scientific
knowledge in homogeneous patient populations/settings
applying rigorous RCT methodology. Such an approach
will permit definitive conclusions regarding the efficacy of
exercise in oncology management. Additionally, as we
move into the era of “personalized medicine” in oncology,
it will be increasingly important to match the exercise pre-
scription to the clinical/treatment characteristics of a patient
subgroup or individual patient. Such a goal is not trivial and
will only be achieved by adopting a translational (bed-to-
benchside) approach to inform mechanistically driven phase
III trials in conjunction with rational correlative science stud-
ies to ensure the optimal safety and efficacy of exercise [44].
In conclusion, there is promising evidence that super-
vised exercise training, compared with usual care (control),
is associated with significant improvements in VO2peak fol-
lowing a diagnosis of select early-stage cancer with mini-
mal AEs, although significant heterogeneity is evident.
Limited evidence is currently available to suggest that the
exerciseVO2peak relationship is different based on exer-
cise intervention or clinical patient characteristics.
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